Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
BEAM Stock Chart & Stats
$25.98
-$0.69(-2.55%)
At close: 4:00 PM EST
$25.98
-$0.69(-2.55%)
Day’s Range― - ―
52-Week Range$13.53 - $35.25
Previous CloseN/A
Volume491.48K
Average Volume (3M)2.63M
Market Cap
$2.61B
Enterprise Value$739.40M
Total Cash (Recent Filing)$1.15B
Total Debt (Recent Filing)$154.80M
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Nov 10, 2025EPS Estimate
-1.04Last Dividend Ex-Date
Feb 04, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding101,162,025
10 Day Avg. Volume2,535,570
30 Day Avg. Volume2,629,582
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue12.27
Enterprise Value/Gross Profit332.62
Enterprise Value/Ebitda-1.86
Forecast
1Y Price Target
$42.20Price Target Upside62.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Financial PerformanceProbability adjusted peak sales increases to approximately $3BN, raising the PT to $35 from $25, reiterating the BUY rating.
Program AdvancementsBEAM has showcased its ability to generate the best-in-class profile in a disease with well characterized underlying disease drivers.
Regulatory EnvironmentBeam stands out as a clear beneficiary of the FDA’s draft guidances, which signal a more enabling regulatory environment for next-generation gene editing technologies.
Bears Say
Competitive RisksThere is a potential risk from competitor CRSP's new preclinical data, which could impact BEAM's stock.
Program ValueThe SCD program for BEAM holds modest value currently, with a key catalyst expected to drive positive outcomes.
Beam Therapeutics News
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $13.53 and its highest was $35.25 in the past 12 months.
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $2.61B.
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is Nov 10, 2025 which is in 23 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Aug 05, 2025. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.113 by $0.113.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics pays a Quarterly dividend of $0.225 which represents an annual dividend yield of N/A. See more information on Beam Therapeutics dividends here
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -1.04.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 101,162,025 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1 in its last earnings report, beating expectations of -$1.113. Following the earnings report the stock price went down -2.197%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Currently, no hedge funds are holding shares in BEAM
Beam Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.20 (62.43% Upside)
$42.20 (62.43% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 388.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $991.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.69%
12-Months-Change
Fundamentals
Return on Equity
-41.94%
Trailing 12-Months
Asset Growth
10.30%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. The company operates in the biotechnology sector, targeting genetic diseases through innovative therapies that aim to correct genetic mutations at the single-base level. Beam's core products include various pipeline candidates designed to treat conditions such as sickle cell disease, beta-thalassemia, and other genetic disorders, leveraging its advanced editing capabilities to provide potentially curative options.
BEAM Stock 12 Month Forecast
Average Price Target
$42.20
▲(62.43% Upside)
Technical Analysis
Denali Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Immunocore Holdings
―
Ownership Overview
1.59% Insiders
17.49% Mutual Funds
0.27% Other Institutional Investors
55.23% Public Companies and Individual Investors